The H5N1 avian influenza antigen and adjuvant maintained their functional integrity in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS), according to testing by the US Biomedical Advanced Research and Development Authority (BARDA).
Vaccines are one of the great success stories of modern medicine. The flu vaccine, however, is a different story. Its effectiveness varies from patient to patient, from population to population, and from year to year.
Health experts should only replenish flu vaccines in areas that need them, researchers argue in a new paper.
As part of our nation’s overall pandemic preparedness strategy, the US Department of Health and Human Services (HHS) set a preparedness goal of establishing and maintaining a stockpile of bulk vaccine antigen and adjuvants for influenza viruses with pandemic potential to vaccinate 26 million people immediately after a pandemic is declared.
The US Biomedical Advanced Research and Development Authority (BARDA) conducted a randomized, double-blinded Phase 2 clinical study with the oldest stockpiled influenza A(H5N1) antigen, stored over the previous 10–12 years administered with or without MF59® adjuvant, stored over the previous 2–7 years at the time of vaccination.
Using electronic medical record (EMR) data from the 2017-2018 flu season, researchers found that a cell-based influenza vaccine was 36.2% more effective than the standard egg-based version in preventing influenza-like illness.
This guidance is intended to provide advice to support planning an effective and consistent pandemic response by States and communities.
Recent research outlines how near-infrared spectroscopy could be used to make cell-culture-based flu vaccine manufacturing faster and more efficient.
Researchers showed that the risk of contracting the flu climbs about 16 percent for every 28 days after vaccination.
The first bout of flu may determine how a person fares during the next pandemic. That’s why scientists are trying to understand immunologic imprinting.